We are (2’R)-2′-Deoxy-2′-fluoro-2′-methyl-uridine CAS:863329-66-2 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: (2'R)-2'-Deoxy-2'-fluoro-2'-methyl-uridine
Molecular Formula: C10H13FN2O5
Molecular Weight: 260.21900
Physical and Chemical Properties:
Density: 1.6±0.1 g/cm3
Melting point: 237-238℃
Flash point: /
Refractive index: 1.596
Appearance: White to off- white powder
Any other impurity:≤0.5%
Loss on Drying:≤1.0%
Residue on ignition:≤1.0%
Acetic acid :≤ 5000ppm
25kg cardboard drum or according to customer specified requirements
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
RO 2433 is the deaminated metabolite of β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine, an effective inhibitor of hepatitis C virus (HCV) replication in vitro.Intermediates of Sofosbuvir CAS:1190307-88-0.
Related News: At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.Octabenzone CAS:1843-05-6 In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.661489-23-2 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.Ácido dibenzo [b, d] tiofeno-4,6-diborónico CAS:1266231-16-2 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.Retrogenix’s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.